Open access · CC-BY
via OpenAlex
Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
Patricia R. Spilman, Natalia Podlutskaya, Matthew J. Hart, Jayanta Debnath, Olivia F. Gorostiza, Dale E. Bredesen, Arlan Richardson, Randy Strong, Verónica Galván
PLoS ONE · 2011 · ▲ 2 citations
Deregulated nutrient-sensing
Altered intercellular communication
Disabled macroautophagy
Rapamycin / mTOR inhibition
Human
Mouse
Abstract
Background: Reduced TOR signaling has been shown to significantly increase lifespan in a variety of organisms [1,2,3,4].It was recently demonstrated that long-term treatment with mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), an inhibitor of the mTOR pathway [5], or ablation of the mTOR target p70S6K[6] extends lifespan in mice, possibly by delaying aging.Whether inhibition of the mTOR pathway would delay or prevent age-associated disease such as AD remained to be determined.Methodology/Principal Findings: We used rapamycin administration and behavioral tools in a mouse model of AD as well as standard biochemical and immunohistochemical measures in brain tissue to provide answers for this question.Here we show that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of Ab 42 , a major toxic species in AD [7], in the PDAPP transgenic mouse model.These data indicate that inhibition of the mTOR pathway can reduce Ab 42 levels in vivo and block or delay AD in mice.As expected from the inhibition of mTOR, autophagy(definition) was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in Ab and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of Ab.Conclusions/Significance: Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.Rapamycin, already used in clinical settings, may be a potentially effective therapeutic agent for the treatment of AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Spilman, P.R., Podlutskaya, N., Hart, M.J., Debnath, J., Gorostiza, O.F., Bredesen, D.E., Richardson, A., Strong, R., & Galván, V. (2011). Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease. <em>PLoS ONE</em>. https://doi.org/10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb
Vancouver
Spilman PR, Podlutskaya N, Hart MJ, Debnath J, Gorostiza OF, Bredesen DE, et al. Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease. PLoS ONE. 2011. doi:10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb.
BibTeX
@article{patricia2011Correc,
title = {Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease},
author = {Patricia R. Spilman and Natalia Podlutskaya and Matthew J. Hart and Jayanta Debnath and Olivia F. Gorostiza and Dale E. Bredesen and Arlan Richardson and Randy Strong and Verónica Galván},
journal = {PLoS ONE},
year = {2011},
doi = {10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
PLoS ONE 2011
Open access · CC-BY
Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
PLoS ONE 2010
Open access · CC-BY
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
Scientific Reports 2018
Open access · CC-BY
Premature recruitment of oocyte pool and increased mTOR activity in Fmr1 knockout mice and reversal of phenotype with rapamycin
Aging Cell 2015
Open access · CC-BY
Sex‐ and tissue‐specific changes in mTOR signaling with age in C57 BL /6J mice
PLoS ONE 2010
Open access · CC-BY
Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease
Frontiers in Genetics 2015
Open access · CC-BY